04.15.20
At the end of March, President Trump signed into law the third coronavirus stimulus legislation, a $2 trillion package known as the Coronavirus Aid, Relief, and Economic Security Act (CARES Act).
04.09.20
On Monday, the Centers for Medicare & Medicaid Services (CMS) released an interim final rule with comment period outlining new flexibilities to pre-existing Medicare and Medicaid payment policies and provider regulations in the midst of the COVID-19 public health emergency (PHE).
02.26.20
In its 2021 Proposed Rule for the Medicare Advantage program, the Centers for Medicare & Medicaid Services (CMS) proposes to alter the rules under which Medicare Advantage Organizations (MAOs) may obtain reinsurance.
12.17.19
The information blocking rule—now moved to the Office of Management and Budget (OMB), the last step before a rule is promulgated—is significant because it reverses the typical framework governing the privacy of health information.
07.22.19
On July 9, Judge Amit P. Mehta of the U.S. District Court, District of Columbia vacated an administration final rule that would have required drug manufacturers to disclose wholesale acquisition prices in their television broadcast advertising.
06.25.19
In May 2018, the President and the Department of Health & Human Services (HHS) rolled out the Drug Pricing Blueprint, outlining the administration’s agenda for dealing with high drug prices.
06.06.19
States are using several different models to extend VBP strategies into their drug purchasing.
05.22.19
On May 8, the administration issued the much-anticipated final rule requiring drug manufacturers to disclose wholesale acquisition prices in their broadcast advertising.
03.25.19
Q: Health Plan A funded a county agency that provides detoxification services to develop a more integrated withdrawal management model for its dually eligible members.
02.14.19
On January 31, the Department of Health & Human Services (HHS) Office of Inspector General (OIG) issued a proposed rule to fundamentally change the system for negotiating drug prices under Medicare Part D and, potentially, for other government and private payers.